Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s What Hedge Funds Think About Meridian Bioscience, Inc. (VIVO)

With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Meridian Bioscience, Inc. (NASDAQ:VIVO).

Meridian Bioscience, Inc. (NASDAQ:VIVO) was in 16 hedge funds’ portfolios at the end of the first quarter of 2019. VIVO investors should be aware of a decrease in support from the world’s most elite money managers of late. There were 18 hedge funds in our database with VIVO positions at the end of the previous quarter. Our calculations also showed that vivo isn’t among the 30 most popular stocks among hedge funds.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 40 percentage points since May 2014 through May 30, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.

CITADEL INVESTMENT GROUP

We’re going to go over the key hedge fund action surrounding Meridian Bioscience, Inc. (NASDAQ:VIVO).

What have hedge funds been doing with Meridian Bioscience, Inc. (NASDAQ:VIVO)?

At Q1’s end, a total of 16 of the hedge funds tracked by Insider Monkey were long this stock, a change of -11% from one quarter earlier. By comparison, 16 hedge funds held shares or bullish call options in VIVO a year ago. With hedge funds’ capital changing hands, there exists a select group of key hedge fund managers who were boosting their holdings considerably (or already accumulated large positions).

No of Hedge Funds with VIVO Positions

When looking at the institutional investors followed by Insider Monkey, Jim Simons’s Renaissance Technologies has the number one position in Meridian Bioscience, Inc. (NASDAQ:VIVO), worth close to $52.9 million, accounting for less than 0.1%% of its total 13F portfolio. The second largest stake is held by D. E. Shaw of D E Shaw, with a $6.8 million position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Some other hedge funds and institutional investors that are bullish comprise Noam Gottesman’s GLG Partners, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital and Ken Griffin’s Citadel Investment Group.

Judging by the fact that Meridian Bioscience, Inc. (NASDAQ:VIVO) has witnessed declining sentiment from the aggregate hedge fund industry, logic holds that there were a few hedgies who sold off their entire stakes heading into Q3. Intriguingly, David Harding’s Winton Capital Management sold off the biggest investment of the 700 funds followed by Insider Monkey, worth about $3.7 million in stock, and Minhua Zhang’s Weld Capital Management was right behind this move, as the fund sold off about $0.6 million worth. These moves are interesting, as total hedge fund interest was cut by 2 funds heading into Q3.

Let’s also examine hedge fund activity in other stocks similar to Meridian Bioscience, Inc. (NASDAQ:VIVO). These stocks are Wabash National Corporation (NYSE:WNC), NV5 Global, Inc. (NASDAQ:NVEE), Mammoth Energy Services, Inc. (NASDAQ:TUSK), and NanoString Technologies Inc (NASDAQ:NSTG). All of these stocks’ market caps are similar to VIVO’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
WNC 16 67949 -4
NVEE 10 25194 -3
TUSK 17 389043 0
NSTG 22 143670 7
Average 16.25 156464 0

View table here if you experience formatting issues.

As you can see these stocks had an average of 16.25 hedge funds with bullish positions and the average amount invested in these stocks was $156 million. That figure was $84 million in VIVO’s case. NanoString Technologies Inc (NASDAQ:NSTG) is the most popular stock in this table. On the other hand NV5 Global, Inc. (NASDAQ:NVEE) is the least popular one with only 10 bullish hedge fund positions. Meridian Bioscience, Inc. (NASDAQ:VIVO) is not the least popular stock in this group but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are piling on. Our calculations showed that top 20 most popular stocks among hedge funds returned 6.2% in Q2 through June 19th and outperformed the S&P 500 ETF (SPY) by nearly 3 percentage points. Unfortunately VIVO wasn’t nearly as popular as these 20 stocks (hedge fund sentiment was quite bearish); VIVO investors were disappointed as the stock returned -33.3% during the same time period and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as 13 of these stocks already outperformed the market so far in Q2.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...